AMGA’s Latest Collaborative Sees Significant Improvement In Adult Pneumococcal and Influenza Vaccination Rates

December 7, 2016

Care providers improve historically low adult vaccination rates, signaling potential to reduce burden

ALEXANDRIA, VA.— AMGA and Optum today announced that their Adult Immunization Best Practices Learning Collaborative, supported by Pfizer, significantly improved adult vaccination rates in a little over one year, as measured against a group of similar providers.  The increase was particularly evident among patients with a high risk for complications related to pneumococcal disease and influenza.

This 14-month pilot program was facilitated by AMGA Foundation, the association’s nonprofit arm, and involved seven AMGA member organizations that use the Optum One population health analytics platform. Through comprehensive integrated data sets, Optum One enabled care providers to proactively identify patients and track performance.

One focus of the collaborative centered on the new CDC guidelines for pneumococcal vaccines in patients age 65 and older. The collaborative was successful in increasing rates of compliance with the guidelines from 4 percent to 34 percent over the course of the 14-month intervention period. This absolute increase of 30 percentage points compares to an increase of 21 percentage points for a matched cohort of care providers in other organizations that are focused on population health but did not participate in the collaborative.

“These results show great promise in helping care providers achieve higher vaccination rates in the older adult population for whom pneumococcal disease can be both serious and deadly,” said Jerry Penso, M.D., chief medical and quality officer of AMGA and president of the AMGA Foundation. “By working together and sharing best practices, these groups have simultaneously demonstrated how to improve the care of patients while preventing disease and the burden associated with it.”

Collaborative participants designed and implemented strategies to identify and address gaps in recommended vaccination practices using intervention tools that target care providers and patients.

“The results of this collaborative are encouraging and will help ensure more people are getting their recommended vaccinations that can help prevent serious disease,” said Virginia McFerran, president, Optum Analytics. “This work demonstrates the strides we can make in patient care by combining data and analytics with population health management techniques.”

Each year in the United States, thousands of adults age 65 and older die from invasive pneumococcal disease including pneumonia, meningitis and bloodstream infections.1 Despite strong public health recommendations supporting adult immunization for vaccine-preventable diseases such as pneumococcal disease, rates among U.S. adults have remained below the U.S. Department of Health and Human Services Healthy People 2020 goals.2

Nearly 50,000 adults in the United States die each year from vaccine-preventable infectious diseases – such as influenza – or their complications.3 Initial data from the collaborative also showed improvement in increasing influenza vaccination rates, but more work with state immunization registries is needed to obtain complete data since many patients receive these vaccines outside their medical group.

Based on the success of this collaborative and the potential to improve these results, AMGA Foundation and Optum – with the support of Pfizer – will launch an expanded collaborative in 2017 that will involve up to 40 AMGA member organizations.

About the Adult Immunization Best Practices Learning Collaborative

In February 2015, AMGA and Optum, with the support of Pfizer, brought together seven AMGA member organizations to collaborate in an effort to improve adult immunization rates for pneumococcal and influenza, thereby reducing the clinical and economic burden of vaccine-preventable diseases. All of the organizations used the same population health tool (OptumTM One), allowing them to systematically track and report progress in a real-world, ambulatory care setting. Case studies from the participating groups are available in the newly released Adult Immunization Best Practices Learning Collaborative Compendium and can be downloaded at http://www.amga.org/wcm/AI2/CS/wcm/PI/Collabs/AI2/cs_ai2.aspx?hkey=5ba4a487-c993-46d7-a155-099fdafe6662. Participants included:

Community Physician Network, Indianapolis, IN

The Iowa Clinic, P.C., West Des Moines, IA

Riverside Medical Group, Newport News, VA

Springfield Clinic, Springfield, IL

SwedishAmerican Health System, Rockford, IL

UMass Memorial Medical Group, Worcester, MA

Watson Clinic, Lakeland, FL

 

Adult Immunization Best Practices Learning Collaborative is a program supported by Pfizer, in partnership with Optum. Learn more about the results of this Collaborative at amga.org/ai2.

 

[1] National Foundation for Infectious Diseases. Facts about Pneumococcal Disease for Adults. http://www.adultvaccination.org/vpd/pneumococcal/facts.html. Accessed Sept. 7, 2016.

[2] US Department of Health and Human Services. Healthy People 2020. https://www.healthypeople.gov/2020/topics-objectives/topic/immunization-and-infectious-diseases. Accessed November 9, 2016.

[3] Trust for America’s Health, Infectious Diseases Society of America, Robert Wood Johnson Foundation. Adult Immunization: Shots to Save Lives. Washington, DC: Trust for America’s Health; February 2010.